List of Excipients in Branded Drug ZALTRAP

ZALTRAP Excipient Strategy and Commercial Opportunities

Last updated: August 10, 2026

ZALTRAP (aflibercept) is an intravenous recombinant fusion-protein product whose commercial excipient opportunity is concentrated in protein-stability technologies, low-peroxide surfactants, high-purity sugars, sterile liquid manufacturing, and ready-to-use delivery formats. The approved formulation uses sucrose, polysorbate 20, phosphate buffering agents, sodium chloride, and water for injection. Its conventional excipient system creates limited composition-of-matter exclusivity but leaves commercial room for suppliers and developers that improve stability, container compatibility, manufacturability, and administration convenience.

What is the ZALTRAP formulation and which excipients does it contain?

ZALTRAP is supplied as a sterile, preservative-free concentrate for intravenous infusion. Each vial contains aflibercept at 25 mg/mL and is available in 100 mg/4 mL and 200 mg/8 mL presentations.[1]

Formulation component	Function	Commercial relevance
Aflibercept	Recombinant therapeutic protein	Active biologic requiring aggregate and particulate control
Sucrose	Stabilizer and tonicity contributor	High-volume, established excipient category
Polysorbate 20	Nonionic surfactant	Controls interfacial adsorption and agitation-induced aggregation
Sodium phosphate salts	Buffer system	Maintains formulation pH
Sodium chloride	Tonicity adjustment	Supports infusion compatibility
Water for injection	Vehicle	Sterile parenteral manufacturing requirement

The product is diluted before intravenous infusion. The label directs dilution in either 0.9% sodium chloride injection or 5% dextrose injection and recommends use within the specified post-dilution handling period.[1]

The excipient system is conventional for a protein therapeutic. That reduces regulatory novelty but also reduces supplier qualification risk. Manufacturers can source established pharmaceutical-grade materials with established compendial and injectable-use histories.

What excipient strategy does ZALTRAP use for protein stability?

ZALTRAP relies on a standard stabilization architecture:

1. Sucrose protects the protein against conformational stress during storage and freezing or drying-related stress.
2. Polysorbate 20 reduces adsorption to vial, syringe, tubing, and infusion-bag surfaces.
3. Phosphate salts control pH, which affects aflibercept aggregation, fragmentation, charge variants, and chemical degradation.
4. Sodium chloride supports isotonicity and infusion tolerability.

For a fusion protein such as aflibercept, the principal formulation risks include aggregation, subvisible particles, oxidation, deamidation, fragmentation, adsorption, and loss of potency. The surfactant is particularly important because therapeutic proteins encounter air-liquid interfaces during vial handling, dilution, transport, and infusion.

Polysorbate 20 also creates a quality-control burden. Peroxide and hydrolysis products can form during storage and may promote protein oxidation or generate particles. This creates a commercial opening for low-peroxide polysorbate 20, tightly specified grades, improved purification processes, and analytical packages that track fatty-acid composition, peroxide value, hydroperoxides, and degradation products.

What formulation patents protect ZALTRAP?

The strongest historic protection for aflibercept has centered on the recombinant protein, its sequence, VEGF-binding activity, and therapeutic use rather than on an unusual excipient combination. The marketed ZALTRAP formulation uses widely used excipients and does not present a clear, commercially distinctive excipient platform based on the FDA prescribing information.[1]

Patent analysis should separate four categories:

Patent category	Relevance to ZALTRAP	Excipient opportunity
Aflibercept composition patents	Protect the fusion protein or related molecules	Limited direct freedom for competing aflibercept products
Protein production patents	Cover host cells, expression, purification, or manufacturing	Opportunities for process licensors and contract manufacturers
Method-of-use patents	Cover treatment of colorectal cancer or other diseases	Relevant to labeling and market segmentation
Formulation patents	Cover concentration, pH, excipients, stability, or delivery	Most relevant to alternative excipient systems

A conventional sucrose, phosphate, sodium chloride, and polysorbate formulation is difficult to protect broadly unless the patent claims a specific concentration range, pH window, stability result, impurity profile, or manufacturing process. A later entrant could pursue a differentiated formulation using, for example, a different surfactant, amino-acid stabilizer, alternative buffer, or lyophilized presentation. That product would still need to establish comparability, potency, purity, safety, and clinical performance.

Public patent databases and FDA product records should be reviewed for issued claims that specifically cover aflibercept concentration, buffer composition, surfactant identity, pH, vial configuration, or dilution stability. The FDA label alone does not establish whether every listed excipient is protected by an enforceable patent claim.

When does ZALTRAP lose exclusivity?

ZALTRAP is a therapeutic protein product originally approved by FDA in August 2012 for use with FOLFIRI in patients with metastatic colorectal cancer whose disease has progressed during or after an oxaliplatin-containing regimen.[1]

Exclusivity issue	Assessment
FDA approval	August 2012
Regulatory pathway	FDA NDA 125418
Product type	Recombinant fusion protein
Traditional small-molecule generic pathway	Not the principal competitive route
Paragraph IV exposure	Generally not the principal route for a follow-on aflibercept product
Biosimilar exposure	Possible through the 351(k) pathway, subject to reference-product and patent requirements
Formulation differentiation	Commercially viable if supported by comparability and stability data

Because ZALTRAP is a complex protein, loss of core patent protection does not automatically produce an interchangeable generic. A follow-on developer must address molecular characterization, biological activity, impurities, immunogenicity, analytical similarity, and clinical or pharmacology requirements under the applicable FDA pathway.

The active ingredient is also marketed in other aflibercept products, including EYLEA for ophthalmic indications. That does not make an EYLEA biosimilar automatically interchangeable with ZALTRAP. Route, concentration, formulation, container, indication, manufacturing process, and reference-product designation remain material.

What is the Orange Book and FDA status of ZALTRAP?

ZALTRAP is identified in FDA records under NDA 125418. Its regulatory history differs from a typical oral small-molecule oncology product because aflibercept is a recombinant protein and the principal competitive question is follow-on biologic development rather than an ordinary ANDA launch.[1]

The Orange Book remains relevant for products approved under an NDA, but Orange Book listing and biologic follow-on competition should not be treated as interchangeable concepts. A potential competitor must determine:

• whether the reference product is listed with relevant patents;
• whether the relevant patent claims cover the active protein, manufacturing method, formulation, or use;
• whether the competing product will use an ANDA, 505(b)(2), or 351(k) strategy;
• whether the product is subject to Purple Book reference-product treatment;
• whether the proposed label can include the relevant indications without method-of-use infringement.

There is no conventional Paragraph IV launch profile comparable to a standard tablet or capsule. A follow-on aflibercept developer would normally focus on biosimilar regulatory strategy, patent dance requirements where applicable, patent-certification issues, and commercial differentiation.

What commercial opportunities exist for ZALTRAP excipients?

Low-peroxide polysorbate 20

This is the most direct excipient opportunity. Suppliers can compete on:

• low peroxide and hydroperoxide levels;
• control of fatty-acid distribution;
• reduced particle formation;
• improved oxidation resistance;
• lot-to-lot consistency;
• validated supply for sterile biologics.

A supplier with strong extractables, leachables, elemental impurity, microbial, and stability data can reduce qualification costs for a follow-on manufacturer.

Alternative surfactants

Poloxamers, polysorbate 80, and newer protein-compatible surfactants could support differentiated formulations. The main barrier is not simple substitution. Each alternative requires evidence that it preserves aflibercept potency and purity across manufacturing, shipping, dilution, and infusion conditions.

A surfactant change can alter subvisible particles, oxidation, container interaction, and immunogenicity risk. That makes this opportunity technically attractive but regulatory-intensive.

Sugar and polyol stabilizers

Sucrose is established in the approved product. Trehalose, mannitol, sorbitol, and selected amino acids could be evaluated for alternative liquid or lyophilized formulations. Trehalose may offer value in freeze-dried presentations, while mannitol can contribute to cake structure and tonicity. These alternatives could support a formulation patent if linked to a defined aflibercept stability profile.

Buffer systems

Phosphate is familiar to regulators but can create precipitation or pH-shift issues under certain conditions. Histidine, citrate, acetate, or other buffers may offer opportunities for improved stability or compatibility. The commercial value depends on maintaining protein integrity after dilution into saline or dextrose infusion solutions.

Ready-to-use delivery systems

ZALTRAP is a concentrate requiring pharmacy preparation. Commercial developers could pursue:

• ready-to-dilute vials;
• prefilled infusion containers;
• dual-chamber systems;
• low-volume concentrated presentations;
• closed-system transfer-compatible packaging;
• stability in infusion bags and administration sets.

The opportunity is strongest where a delivery system reduces preparation time, drug waste, contamination risk, or occupational exposure. A device-based product may receive protection through container, closure, device, or use patents rather than through the excipient formulation alone.

What manufacturing and intellectual-property barriers affect alternative formulations?

The key manufacturing barriers are aseptic processing, protein aggregation control, sterile filtration, low-bioburden excipient supply, container-closure compatibility, and scale-up reproducibility.

A successful alternative formulation must control critical quality attributes, including:

Quality attribute	Primary formulation concern
Potency	Retention of VEGF-binding and biological activity
Purity	Aggregates, fragments, and charge variants
Particulates	Surfactant degradation, protein particles, and silicone interaction
Chemical stability	Oxidation, deamidation, hydrolysis, and glycation
Sterility	Aseptic processing and container integrity
Compatibility	Dilution in saline or dextrose and infusion-set contact
Immunogenicity risk	Product-related impurities and structural changes

Patent opportunities are more credible when claims combine a specific aflibercept concentration with a defined excipient range, pH, storage condition, and measurable stability result. Broad claims covering sucrose or polysorbate 20 alone would face substantial prior-art pressure.

Trade-secret protection may be more practical for surfactant purification, mixing order, hold times, oxygen control, filtration parameters, and filling conditions. These process controls can materially affect product quality while remaining difficult to reverse engineer.

How does the ZALTRAP excipient opportunity compare with EYLEA?

ZALTRAP and EYLEA contain the same active fusion-protein class, but they serve different routes and clinical markets. ZALTRAP is administered intravenously in oncology, while EYLEA is administered intravitreally in ophthalmology.[1,2]

Factor	ZALTRAP	EYLEA
Route	Intravenous infusion	Intravitreal injection
Primary market	Metastatic colorectal cancer	Retinal vascular and macular diseases
Presentation	Concentrate for dilution	Small-volume ophthalmic injection
Excipient priorities	Infusion compatibility, dilution stability, protein aggregation	Ocular tolerability, syringeability, particulate control
Commercial differentiation	Ready-to-use infusion and lower preparation burden	Prefilled syringes, higher concentration, injection convenience
Biosimilar complexity	Oncology follow-on protein	Ophthalmic follow-on protein with route-specific requirements

A supplier strategy for ZALTRAP should not simply replicate an EYLEA formulation strategy. The relevant performance requirements differ. ZALTRAP developers should prioritize infusion-bag stability, pharmacy workflow, and large-volume manufacturing. EYLEA-oriented developers prioritize low injection volume, ocular tolerability, syringe delivery, and prefilled-device performance.

Which companies can capture value from ZALTRAP excipient demand?

The commercial field includes four groups:

1. Specialty excipient manufacturers supplying low-peroxide polysorbate 20, pharmaceutical sucrose, buffers, and amino-acid stabilizers.
2. Contract development and manufacturing organizations with biologics formulation and aseptic filling capabilities.
3. Container and delivery-system suppliers offering ready-to-use infusion formats.
4. Follow-on biologic developers seeking differentiation through stability, administration, or manufacturing economics.

The most defensible value proposition is an integrated package: excipient grade, analytical characterization, formulation screening, container compatibility, and regulatory documentation. Commodity supply alone has limited strategic value because the approved excipients are widely available.

What generic and biosimilar launch risks exist for ZALTRAP?

The primary risk is a follow-on aflibercept product that achieves acceptable analytical similarity and competes through price, supply reliability, or a differentiated presentation. The risk is moderated by:

• complexity of aflibercept characterization;
• manufacturing scale and process knowledge;
• clinical development requirements;
• patent and regulatory timing;
• payer acceptance;
• physician confidence in oncology biologics;
• the need to establish a reliable sterile supply chain.

A lower-cost formulation is unlikely to win solely through excipient substitution. The stronger strategy combines an optimized formulation with manufacturing efficiency, reduced drug waste, or easier pharmacy preparation.

Key Takeaways

• ZALTRAP uses a conventional protein formulation based on sucrose, polysorbate 20, phosphate buffering agents, sodium chloride, and water for injection.
• Low-peroxide polysorbate 20 is the clearest near-term excipient opportunity.
• Alternative buffers, surfactants, sugars, and polyols could support differentiated formulations, but they require extensive comparability and stability evidence.
• Ready-to-use infusion presentations may create greater commercial value than excipient substitution alone.
• ZALTRAP competition is primarily a follow-on biologic issue, not a conventional Paragraph IV generic issue.
• Patent strength is more likely to reside in aflibercept composition, manufacturing, use, or defined formulation claims than in individual commodity excipients.
• The strongest commercial package combines excipient supply, formulation development, analytical control, container compatibility, and sterile manufacturing.

FAQs

Can polysorbate 20 be replaced in ZALTRAP?

Yes, a developer could evaluate another surfactant, but replacement would require evidence of equivalent or improved stability, potency, purity, particle control, and infusion compatibility.

Is sucrose in ZALTRAP patent-protected by itself?

Sucrose as a common pharmaceutical excipient is not likely to provide meaningful standalone protection. A patent may still claim a specific aflibercept formulation containing sucrose within defined concentration, pH, and stability parameters.

Could a prefilled ZALTRAP infusion product obtain separate patent protection?

Potentially. Protection could focus on the container, closure, infusion device, concentration, storage condition, or administration method. Regulatory approval would still require container-closure, sterility, compatibility, and stability data.

Does an aflibercept ophthalmic biosimilar automatically compete with ZALTRAP?

No. Aflibercept products with different routes, formulations, indications, and reference products are not automatically interchangeable. The regulatory and commercial analysis must be product-specific.

Which excipient has the highest strategic value for a ZALTRAP follow-on product?

Low-peroxide polysorbate 20 has the clearest value because surfactant degradation can affect oxidation and particulate formation. Its advantage increases when supported by validated stability data and a reliable sterile supply chain.

References

1. U.S. Food and Drug Administration. (2023). ZALTRAP (ziv-aflibercept) injection, prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125418s045lbl.pdf

2. U.S. Food and Drug Administration. (2023). EYLEA (aflibercept) injection, prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125387s078lbl.pdf

3. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov/

4. International Council for Harmonisation. (1995). Q5C: Quality of biotechnological products: Stability testing of biotechnological/biological products. https://database.ich.org/sites/default/files/Q5C_Guideline.pdf

5. International Council for Harmonisation. (1999). Q6B: Specifications: Test procedures and acceptance criteria for biotechnological/biological products. https://database.ich.org/sites/default/files/Q6B_Guideline.pdf